Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
Fast Track designation awarded by the FDA serves as an external validation of the potential of NOX-A12 for unmet need in…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
The exercise of Warrants Z follows a successfully completed capital increase with preferential subscription rights throu…
Clinical trial protocol approved in the US to initiate Phase 2 study with NOX-A12 in glioblastoma providing a clear road…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
€1.48 million private placement secured from a group of new investors Buyback will mark the end of TME Pharma's converti…
TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatm…
Constructive meeting held with FDA provided feedback and clear guidance on key aspects of further development of NOX…